The Future of Hepatitis C Virus Treatment: Implications for Specialty and Community Pharmacy

Pharmacy Times, February 2015 Autoimmune Disorders, Volume 81, Issue 2

This continuing education activity is supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

This activity is supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

The Future of Hepatitis C Virus Treatment: Implications for Specialty and Community Pharmacy

Michael Crowe, PharmD, MBA, CSP, FMPA

Adjunct Assistant Professor of Clinical Pharmacy

Ferris State University College of Pharmacy

Clinical Technology Manager Diplomat Pharmacy

Flint, Michigan

Educational Objectives:

After completing this continuing education program, the participant should be able to:

  • Outline the progression of hepatitis C virus (HCV) infection from acute to chronic infection, including its clinical presentation and complications.
  • Summarize the Centers for Disease Control guidelines for HCV screening and the role of the pharmacist in identifying those at risk and engaging them in treatment.
  • Identify an appropriate treatment regimen for a patient diagnosed with chronic HCV infection, given virus and patient characteristics, and counsel the patient on expectations for the selected regimen.
  • Recall the safety and efficacy of chronic HCV treatments currently in the pipeline with those available today.

Target audience:

Community Pharmacists & Specialty Pharmacists

Type of activity:

Knowledge

Release date:

February 6, 2015

Expiration date:

February 6, 2017

Estimated time to complete activity:

2.0 hours

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-010-H01-P. The activity is available for CE credit through February 6, 2017.